JP2013532725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532725A5 JP2013532725A5 JP2013523129A JP2013523129A JP2013532725A5 JP 2013532725 A5 JP2013532725 A5 JP 2013532725A5 JP 2013523129 A JP2013523129 A JP 2013523129A JP 2013523129 A JP2013523129 A JP 2013523129A JP 2013532725 A5 JP2013532725 A5 JP 2013532725A5
- Authority
- JP
- Japan
- Prior art keywords
- hcv
- methyl
- interferon
- pyrrolidinyl
- additional compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 108010050904 Interferons Proteins 0.000 claims 8
- 102000014150 Interferons Human genes 0.000 claims 8
- 229940079322 interferon Drugs 0.000 claims 8
- -1 7-((2-((2S, 5S) -1-((2S) -2- (4,4-difluorocyclohexyl) -2-((methoxy Carbonyl) amino) acetyl) -5-methyl-2-pyrrolidinyl) -1H-benzimidazol-5-yl) ethynyl) -1H-naphtho [1,2-d] imidazol-2-yl Chemical group 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 108010047761 Interferon-alpha Proteins 0.000 claims 4
- 102000006992 Interferon-alpha Human genes 0.000 claims 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 229960000329 ribavirin Drugs 0.000 claims 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- HAEJPQIATWHALX-KQYNXXCUSA-N ITP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HAEJPQIATWHALX-KQYNXXCUSA-N 0.000 claims 2
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 claims 2
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 2
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 2
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 2
- 102000012479 Serine Proteases Human genes 0.000 claims 2
- 108010022999 Serine Proteases Proteins 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 2
- 229960003805 amantadine Drugs 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 2
- 229960002751 imiquimod Drugs 0.000 claims 2
- 230000002452 interceptive effect Effects 0.000 claims 2
- 229940117681 interleukin-12 Drugs 0.000 claims 2
- 229940100601 interleukin-6 Drugs 0.000 claims 2
- 150000004712 monophosphates Chemical class 0.000 claims 2
- 229960000888 rimantadine Drugs 0.000 claims 2
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2010/044356 WO2012018325A1 (en) | 2010-08-04 | 2010-08-04 | Hepatitis c virus inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013532725A JP2013532725A (ja) | 2013-08-19 |
| JP2013532725A5 true JP2013532725A5 (https=) | 2013-09-26 |
| JP5596861B2 JP5596861B2 (ja) | 2014-09-24 |
Family
ID=43640063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013523129A Expired - Fee Related JP5596861B2 (ja) | 2010-08-04 | 2010-08-04 | Ｃ型肝炎ウイルス阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2601188B1 (https=) |
| JP (1) | JP5596861B2 (https=) |
| KR (1) | KR20140045903A (https=) |
| CN (1) | CN103153986B (https=) |
| AU (1) | AU2010358561B2 (https=) |
| BR (1) | BR112013002729A2 (https=) |
| CA (1) | CA2807305A1 (https=) |
| EA (1) | EA022127B1 (https=) |
| IL (1) | IL224298A (https=) |
| MX (1) | MX337936B (https=) |
| SG (1) | SG187183A1 (https=) |
| WO (1) | WO2012018325A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8673954B2 (en) * | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| AU2010274001A1 (en) | 2009-07-16 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of Flavivirus infections |
| CN102869657A (zh) | 2010-03-24 | 2013-01-09 | 沃泰克斯药物股份有限公司 | 用于治疗或预防黄病毒感染的类似物 |
| US8859595B2 (en) | 2010-08-26 | 2014-10-14 | Rfs Pharma, Llc | Potent and selective inhibitors of hepatitis C virus |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2012158861A2 (en) | 2011-05-18 | 2012-11-22 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2013217224B2 (en) | 2012-02-10 | 2017-04-06 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| EP2850072B1 (en) | 2012-04-25 | 2016-08-31 | Theravance Biopharma R&D IP, LLC | Hepatitis c virus inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9775831B2 (en) | 2013-07-17 | 2017-10-03 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of HCV |
| WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| KR20200009001A (ko) | 2017-05-17 | 2020-01-29 | 가부시끼가이샤 도꾸야마 | 디아미노벤젠 화합물의 제조 방법 |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| AU2019292883A1 (en) | 2018-06-28 | 2021-01-14 | Tokuyama Corporation | Method for producing α-azidoaniline derivative or α, α'-diazide derivative |
| CN113631560B (zh) | 2019-03-15 | 2025-02-18 | 麦迪穆有限责任公司 | 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830905A (en) * | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
| US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| AU2003264038A1 (en) | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Combination pharmaceutical agents as inhibitors of hcv replication |
| BR0314640A (pt) * | 2002-09-20 | 2005-08-02 | Kirin Brewery | Inibidor de vìrus de hepatite c compreendendo, como um ingrediente ativo, alfa-glicosilceramida |
| WO2006093867A1 (en) | 2005-02-28 | 2006-09-08 | The Rockefeller University | Structure of the hepatitits c virus ns5a protein |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) * | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2750577A1 (en) * | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| TWI438200B (zh) * | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
-
2010
- 2010-08-04 SG SG2013005558A patent/SG187183A1/en unknown
- 2010-08-04 CA CA2807305A patent/CA2807305A1/en not_active Abandoned
- 2010-08-04 MX MX2013001237A patent/MX337936B/es active IP Right Grant
- 2010-08-04 KR KR1020137005316A patent/KR20140045903A/ko not_active Abandoned
- 2010-08-04 EP EP10740116.8A patent/EP2601188B1/en not_active Not-in-force
- 2010-08-04 CN CN201080069468.6A patent/CN103153986B/zh not_active Expired - Fee Related
- 2010-08-04 JP JP2013523129A patent/JP5596861B2/ja not_active Expired - Fee Related
- 2010-08-04 EA EA201370017A patent/EA022127B1/ru not_active IP Right Cessation
- 2010-08-04 WO PCT/US2010/044356 patent/WO2012018325A1/en not_active Ceased
- 2010-08-04 BR BR112013002729A patent/BR112013002729A2/pt not_active IP Right Cessation
- 2010-08-04 AU AU2010358561A patent/AU2010358561B2/en not_active Ceased
-
2013
- 2013-01-17 IL IL224298A patent/IL224298A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013532725A5 (https=) | ||
| JP2012523415A5 (https=) | ||
| JP2013510853A5 (https=) | ||
| JP2012528161A5 (https=) | ||
| JP2012512169A5 (https=) | ||
| HRP20160410T1 (hr) | Inhibitori hepatitis c virusa | |
| JP2014504643A5 (https=) | ||
| JP2013521279A5 (https=) | ||
| US8426458B2 (en) | Hepatitis C Virus inhibitors | |
| US9060971B2 (en) | Combination pharmaceutical agents as inhibitors of HCV replication | |
| JP2012504132A5 (https=) | ||
| US10017499B2 (en) | Benzimidazole derivatives | |
| US8101643B2 (en) | Benzimidazole derivatives | |
| JP2012518000A5 (https=) | ||
| HRP20120440T1 (hr) | Inhibitori virusa hepatitisa c | |
| JP2012504632A5 (https=) | ||
| JP2011511841A5 (https=) | ||
| EA022127B1 (ru) | Ингибиторы вируса гепатита с | |
| HRP20130063T1 (hr) | Inhibitori virusa hepatitisa c | |
| JP2015535853A5 (https=) | ||
| JP2013514359A5 (https=) | ||
| JP2012504126A5 (https=) | ||
| JP2011530531A5 (https=) | ||
| JP2011521965A5 (https=) | ||
| JP2014515377A5 (https=) |